References
Giovanelli M., Losa M., Mortini P. Acromegaly: surgical results and prognosis. In: Landolt A.M., Vance M.L., Reilly P.L. (Eds.), Pituitary adenomas. Churchill Livingstone, Edinburgh, 1996, pp. 333–351.
Ezzat S., Snyder P.J., Young W.F., Boyajy L.D., Newman C. Klibanski A., Molitch M.E., Boyd A.E., Sheeler L., Cook D.M., Malarkey W.B., Jackson I., Vance M.L., Thorner M.O., Barkan A., Frohman L.A., Melmed S. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann. Intern. Med. 1992, 117: 711–718.
Spinas G.A., Zapf J., Landolt A.M., Stuckmann G., Froesch E.R. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol. (Copenh.) 1987, 114: 249–256.
Fahlbusch R., Giovanelli M., Buchfelder M., Losa M., and the participants of the “Conference on medical and surgical treatment of pituitary adenomas” (Zürich, 5th October 1991). Advances in the medical and surgical treatment of pituitary adenomas: The role of long-acting somatostatin analogs. J. Endocrinol. Invest. 1993, 16: 449–460.
Barkan A.L., Lloyd R.V., Chandler W.F., Hatfield M.K., Gebarski S., Kelch R.P., Beitins I.Z. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J. Clin. Endocrinol. Metab. 1988 67: 1040–1048.
Plöckinger U., Reichel M., Fett U., Saeger W., Quabbe H.-J. Preoperative octreotide treatment of growth hormonesecreting and clinically nonfunctioning pituitary macroadenomas: effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metab. 1994, 79: 1416–1423.
Lucas-Morante T., Garcia-Uria J., Estrada J., Saucedo G., Cabello A., Alcañiz J., Barceló B. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J. Neurosurg. 1994, 81: 10–14.
Stevenaert A., Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism 1996, 45: 72–74.
Colao A., Ferone D., Cappabianca P., del Basso De Caro M.L., Marzullo P., Monticelli A., Alfieri A., Merola B., Calì A., de Divitiis E., Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. J. Clin. Endocrinol. Metab. 1997, 82: 3308–3314.
Merola B., Cittadini A., Colao A., Ferone D., Fazio S., Sabatini D., Biondi B., Saccà L., Lombardi G. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J. Clin. Endocrinol. Metab. 1993, 77: 790–793.
Lamberts S.W.J., van der Lely A.-J., de Herder W.W., Hofland L.J. Octreotide. N. Engl. J. Med. 1996, 334: 246–254.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Losa, M., Mortini, P. & Giovanelli, M. Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?. J Endocrinol Invest 22, 871–873 (1999). https://doi.org/10.1007/BF03343662
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343662